Cancer variant calling workflow with mutect and changes/additions to the GATK best practices
I'm working on a cancer variant calling workflow (DNAseq) with MuTect as the variant caller, rather than HaplotypeCaller (due to it's low AF intolerance).
I've gone through the forum and couldn't find a full answer to my inquiry. My question has 2 parts actually:
what changes/additions should I implement in my pipeline/workflow to the GATK Best practices workflow for variant analysis to make it more suitable for cancer variant calling with MuTect, taking into account that I don't have a normal tissue sample, just tumor and an hg19 reference from the bundle:
Is there a difference between the recommended "--known" variants/sites of the GATK's best practices workflow for general variant calling and the one for cancer variant calling with MuTect as the variant caller? Specifically to this article:
Thank you very much in advance,